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Cancer is a communal health hazard worldwide. The present investigation attempts to evaluate anti-
microbial and anticancer potential of kosinostatin on mammary carcinoma cell line (MCF-7). The an-
ticancer and antiproliferative activities of kosinostatin were analyzed on MCF cell line by MTT assay and
cytotoxicity assays like lactate dehydrogenase (LDH) and glutathione (GSH). The secondary metabolite
kosinostatin exhibited its apoptotic nature by expressing p53 protein. Collectively, the results acquired
from this study promise that kosinostatin shows the potent anticancer activity.
& 2015 Xi'an Jiaotong University. Production and hosting by Elsevier B.V. All rights reserved. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Natural products are inspiration for a signiﬁcant quantity of the
new small-molecule chemical entities established as drugs. Mi-
crobial natural products are an important source of both existing
and new drugs [1]. Investigation into prokaryotic and eukaryotic
organisms produced natural products with pharmacological and
medicinal possessions shows the way for clinical consequence.
Antibiotics and analogous natural products, being secondary
metabolites, have been regarded as imperative resources that could
produce potential chemotherapeutic agents [2]. The convenient
signiﬁcance of antibiotics and other secondary metabolites is re-
markable in that they are widely used in the human therapies in-
cluding antibacterial, antifungal, antiprotozoal, antinematode, an-
ticancer, antiviral and anti-inﬂammatory activities [3]. A ﬁla-
mentous, non-motile Gram-positive bacterium, Actinomycetes, is
known to produce secondary metabolite which has valuable clinical
traits [4,5]. The species belonging to the genus Streptomyces are
known to produce a greater number of discovered bioactive sec-
ondary metabolites acting as antibiotics, antiviral drugs, herbicides,
insecticides, antitumor agents and immunomodulators agents [6,7].
Cancer is a class of disease in which a group of cells display the
traits of uncontrolled proliferation of cells. Nearly all cancers areon and hosting by Elsevier B.V. All
University.
: þ91 4374239328.
(S. Vijayakumar).caused by abnormalities in the genetic material of the transformed
cells [8]. Breast cancer is the primary cause of cancer-related death
in women, and one in 10 of all new cancers is diagnosed world-
wide each year [9]. The progress of breast cancer is coupled with
modiﬁcation of the fragile equilibrium between cell propagation
and apoptotic cell death, cellular redox status, deregulation of
cellular differentiation and endocrine derangement [10,11].
Natural products are still important sources to discover new
anticancer agents, mainly secondary metabolites, produced by or-
ganisms in response to external stimuli such as nutritional changes,
infection and competition. Natural products produced by plants,
fungi, bacteria, insects and animals have been isolated as biologi-
cally active pharmacophores. Kosinostatin, a quinocycline antibiotic
(Fig. 1), was isolated from the culture ﬁltrate of Streptomyces vio-
laceusniger strain HAL64. Kosinostatin inhibits the growth of Gram-
positive bacteria strongly and Gram-negative bacteria and yeasts
moderately. It shows cytotoxicity against various cancer cell lines
and inhibits human DNA topoisomerase Ila [12]. The present in-
vestigation signiﬁes antimicrobial and anticancer potential of kosi-
nostatin against mammary carcinoma cell line (MCF-7).2. Materials and methods
2.1. Drug and materials
Dimethyl sulfoxide (DMSO) was purchased from Med Koo
Biosciences, Inc., Chapel Hill, North Carolina, USA. RPMI-1640,rights reserved. This is an open access article under the CC BY-NC-ND license
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Fig. 1. The chemical structure of kosinostatin (Quinocycline B).
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lin, Germany. Kosinostatin and ethidium bromide were purchased
from Sigma-Aldrich, Bangalore, India. Human mammary carcinoma
cell line (MCF-7) was obtained from National Center for Cell Sci-
ences (NCCS), Pune, India. Penicillin–streptomycin and fetal bovine
serum were purchased from Gibco, Germany. Trypsin–Ethylene
diamine tetra acetic acid (EDTA) was obtained from Hi-media La-
boratories, Mumbai, India. Cell culture plates and dishes were
purchased from TPP, Trasadingen, Canton, Switzerland. Rabbit anti-
mouse immunoglobulin (IgG) was purchased from Genei, Banga-
lore, India. Nitrocellulose membrane and polyvinylidene diﬂuoride
(PVDF) membrane were purchased from Millipore Co., MA, USA.
Primary antibodies (Ab's) p53 were purchased from Abcam, Cam-
bridge, USA. All other chemicals including solvents were of highest
purity and of analytical grade marketed by Glaxo Laboratories and
SISCO Research Laboratories (SRL), Mumbai, India.
2.2. Instrumentation
The MTT assay was done using ELx800 Absorbance Microplate
Reader, BioTek Instruments, India. Lactate dehydrogenase (LDH)
assay was determined using Biochemical Analysis System Mindray
BS-420, Shanghai, China. Estimation of GSH was done using a TOC
analyzer (TOC-VCPN 5000A, Shimadzu, Japan).
2.3. Drug preparation
Kosinostatin was dissolved in DMSO (the ﬁnal concentration of
DMSO was not exceeded 0.1% (v/v) and did not affect the cell
survival), prepared in serum-free Roswell Park Memorial Institute
(RPMI) medium, ﬁltered by a 0.045 mm syringe ﬁlter and stored at
4 °C.
2.4. Agar well diffusion and determination of minimum inhibitory
concentration (MIC)
Bacterial broth culture was prepared to a density of
108 cells/mL and the aliquot was spread evenly by L rod onto
Muller Hinton agar. Then, the plated medium was allowed to dry
at room temperature for 30 min. Kosinostatin (5 μM and 10 μM)
was aseptically introduced into an agar well and the plates were
incubated at 37 °C for 24 h. The formation of clear inhibition zone
on the Muller Hinton agar was measured. The experiment was
performed in triplicate.
2.5. Human MCF-7 maintenance and treatment
Human MCF-7 cells were routinely grown as monolayer cul-
tures at 37 °C in a humidiﬁed atmosphere of 5% CO2 and 95% O2 in
Dulbecco Modiﬁed Eagles Medium (DMEM) containing 10% (v/v)fetal bovine serum (FBS), penicillin (50 IU) and streptomycin
(50 mg/mL). Kosinostatin was dissolved in DMSO, prepared in
DMEM, ﬁltered by a 0.045 mm syringe ﬁlter and stored at 4 °C for
the cell culture protocols.
2.6. MTT cell viability assay
MCF-7 cells were seeded in 96 well microplate (1104 cells/
well in 180 mL medium) and routinely cultured in a humidiﬁed
incubator (37 °C in 95% CO2) for 24 h. Kosinostatin (1, 2, 5 and
10 μM) was added in a serial concentration and re-incubated for
24 h. MTT (3-(4,5 dimethyl thiozal-2-yl)-2,5-diphenyl tetrazolium
bromide) assay was performed as described [13]. The viability of
the cells was assessed by MTT assay, which was based on the re-
duction of MTT by the mitochondrial dehydrogenase of intact cells
to a purple formazan product. Then the medium was discarded
and 30 mL of tetrazolium dye (5 mg/mL in PBS) was added to every
well and re-incubated for 4 h. After removing the un-transformed
MTT reagent, 100 mL of DMSO was added to dissolve the formazan
crystals formed. The amount of formazan was determined by
measuring the absorbance at 570 nm using an ELISA reader.
The percentage of cell survival was calculated by the following
formula:
Cell survival %
Mean absorbance from treated cells
Mean absorbance from untreated cells
100( ) = ×
The cells were incubated at 37 °C in a controlled humidiﬁed at-
mosphere of 5% CO2 and 95% air for 48 h and the following ex-
periments were carried out.
2.7. LDH leakage assay
LDH assay was performed by the method reported by Grivell
et al. [14]. LDH activity was expressed as moles of NADH used per
minute per well. Based on the above studies, kosinostatin at the
concentrations of 5 and 10 μM was selected for further
experiments.
2.8. Estimation of glutathione (GSH)
Total reduced glutathione was determined by the method re-
ported by Moron et al. [15]. 1 mL of 5% TCA was added to human
hepatoma cell line (1106 cells). The precipitate was removed by
centrifugation. To an aliquot of the supernatant, 2 mL of 5,5′-di-
thiobis-(2-nitrobenzoic acid) (DTNB) reagent was added to make a
ﬁnal volume of 3 mL. The absorbance was read at 412 nm against a
blank containing TCA instead of sample. Aliquots of the standard
solution were treated similarly. The amount of reduced glu-
tathione was expressed as μg of GSH/mg protein.
2.9. Quantiﬁcation of protein concentration
The total protein concentration in MCF-7 cells (control and allyl
isothiocyanate (AITC) treated cells) was quantiﬁed by the method
reported by Lowry et al. [16] using bovine serum albumin (BSA) as
a standard. The protein concentration in cell lysate was expressed
as mg protein.
2.10. Expression of p53 proteins by Western blotting analysis
MCF-7 cells (1106/mL) were treated with the AITC at the
concentrations of 2, 5 and 10 μM for 48 h at 37 °C. Cells were lysed
with 10 μL of lysis buffer. Cell proteins were separated in sodium
dodecyl sulfate polyacrylamide gel elecrophorosis (SDS-PAGE). 4%
stacking gel and 10% resolving gel were used to separate the
proteins. After electrophoresis, gel was placed over a nitrocellulose
Fig. 3. MTT cell viability assay on control and kosinostatin treated MCF-7 cell line.
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gel and the PVDF membrane were packed by three cut-pieces of
Whatman ﬁlter paper (No.3). The arrangement was covered on
both sides with absorbers (provided with the system) and clipped.
The arrangement was immersed in a tank containing blotting
buffer. A current of 25 mA was passed through overnight.
Then, the membranes were removed from the system and
immersed in methanol for a minute. The membranes were blocked
by treating with the blocking buffer for 1 h at 37 °C. After washing,
the membranes were incubated with anti-mouse p53 (1:100) and
anti-mouse caspase-3 (1:1000) for 6 h at 37 °C. After three washes
in phosphate buffered solution (PBS)/0.1% Tween 20, the mem-
branes were incubated with Horse Raddish Peroxidase (HRP)
conjugated anti-mouse IgG antibody for 1 h at 37 °C. The protein
bands appeared were then visualized and photographed. The band
intensity for p53 was normalized with that of the internal control
β actin.Fig. 4. Level of LDH leakage in control and kosinostatin treated MCF-7 cell lines.3. Results
In the present study, the evaluation of antibacterial activity of
kosinostatin was studied using agar well diffusion method. The
results revealed variability in the inhibitory concentration of each
concentration against pathogenic bacteria. Kosinostatin showed
signiﬁcant antimicrobial activity against Candida albicans, Micro-
coccus luteus and Saccharomyces cervicea, but it showed minimum
zone of inhibition against Staphylococcus aureus and Bacillus sub-
tilis when compared with the previously mentioned genus. Kosi-
nostatin at a concentration of 10 μM showed signiﬁcant effect
compared with that at 5 μM. Thus, it revealed dose-dependent
inhibitory pattern against the above mentioned microorganisms
(Fig. 2).
3.1. MTT cell viability assay
The result shown in Fig. 3 is the cell viability of control and
kosinostatin treated (1, 2, 3, 5 and l0 μM) MCF-7 cells. Kosinostatin
noticeably inhibited the mammary cells after 24 h of treatment.
The results showed that the treatment with kosinostatin markedly
reduced the viability of MCF-7 cells in a dose-dependent manner.
3.2. Lactate dehydrogenase (LDH) leakage
The levels of LDH released into the medium of control and
kosinostatin treated (5, 10 μM) MCF-7 cells are presented in Fig. 4.
From the result, it was observed that LDH activities signiﬁcantly
elevated (po0.05) in the medium containing 10 μM of kosinos-
tatin when compared to the control.Fig. 2. Determination of minimum inhibitory concentration (MIC).3.3. GSH level
It is well known that the toxicity of anti-proliferating drugs
may basically depend on the intracellular level of reduced GSH
[17]. GSH has an important activity in protecting cells and cellular
components against oxidative damage as well as in detoxiﬁcation.
It is often found that GSH levels are increased in the drug resistant
cancer cells when compared to the drug sensitive cells. Inhibition
of GSH synthesis or modulation of GSH storages in tumors to re-
duce anticancer drugs resistance might contain a novel anticancer
strategy [18]. The levels of GSH content in control and kosinostatin
treated MCF-7 cells were estimated. The result revealed signiﬁcant
(po0.05) depletion of GSH in kosinostatin treated mammary cells
at the concentrations of 5 and 10 μM when compared to the
control cells (Fig. 5).3.4. Expression of p53 proteins
The p53 gene was involved as a regulator in the process of
apoptosis. After DNA damage in cell types, p53 can trigger the
genetically altered cells to be eliminated by inducing apoptosis
[19]. In addition to its DNA damage response, p53 is also involved
in the response by abnormal or stress conditions such as hypoxia
and oxidative stress. The expression of p53 in control and kosi-
nostatin treated (2, 5 and 10 μM) MCF-7 cells by Western blotting
is presented in Fig. 6. Treatment of kosinostatin on MCF-7 cells
showed an increased band intensity of 53 kDa protein compared
to the control. The accumulation of p53 protein indicated the ex-
pression of tumor suppressor protein induced apoptosis by kosi-
nostatin on MCF-7 cells. This result strongly suggested that kosi-
nostatin treatment stimulated the apoptosis.
Fig. 5. Level of GSH in control and kosinostatin treated MCF-7 cells.
Fig. 6. Western blotting analysis of control and kosinostatin treated MCF-7 cells.
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The result of MIC revealed that kosinostatin (5 and l0 μM) was
active against C. albicans, S. cervicea, M. luteus, S. aureus, and B.
subtilis.
The reason for different sensitivities between fungus and bac-
teria could be ascribed to the morphological differences between
these microorganisms, Gram-positive bacteria having only an
outer peptidoglycan layer which is not an effective permeability
barrier [20]. The reason for different sensitivities between bacteria
could be attributed to the morphological differences between
these microorganisms [21]. Kosinostatin might inhibit the fungi
through interfering with germination and ﬁlamentous formation
[22]. From our result, it could be concluded that kosinostatin has a
higher ability to inhibit fungi than inhibit bacteria in a dose-de-
pendent manner.
The progress in drug resistance phenotype is accompanied by
the changes in different biological features of malignant cells, in-
cluding morphological ones. In vitro screening models provide
preliminary data in selecting the drugs for clinical trials [23]. The
cytotoxic cells were grown under controlled conditions, outside of
their natural environment. In this assay, cell death and cell viabi-
lity were estimated [24]. The antiproliferative activity and cyto-
toxicity of kosinostatin against MCF-7 cell lines were determined
by MTT assay [25]. This analysis revealed the anticancer potential
of kosinostatin in MCF-7 cells. Kosinostatin at a concentration of
5 mM shows a good evidence that it is cytotoxic to cancer cells. The
kosinostatin treated group showed a decrease in viability of MCF-
7. Streptomyces sp. secondary metabolites reduced the cell viability
in a dose-dependent manner. The secondary metabolite reduced
the cell viability up to 50% at the concentrations of 5 and 10 mM on
MCF-7 cells and the inhibition was in a dose-dependent manner,
which signiﬁes that kosinostatin has better antiproliferative ac-
tivity towards mammary carcinoma cell line at minimum con-
centration. The various compounds such as vitamins, carotenoids,
terpenoids, ﬂavonoids, polyphenols, alkaloids, tannins, saponins,
enzymes and minerals might be responsible for the anti-
proliferative activity [26].LDH activity was determined by the colorimetric method [27],
and LDH leakage analysis was performed to conﬁrm cytotoxicity of
the drug [28]. Results of LDH cytotoxicity assay revealed that the
treatment of cancer cells with kosinostatin caused the increase of
cytotoxicity. The LDH assay also revealed that the cytotoxicity was
increased in the kosinostatin secondary metabolite treated group
of both MCF-7 cells. Kosinostatin treated cells prove the cytotoxic
nature of secondary metabolites by leakage of LDH. As the con-
centration of kosinostatin was elevated, the release of LDH also
increased in a concentration-dependent manner [29]. Since lactate
release of tumor cells is thought to be related to the glycolytic shift
of cells contributing to the tumor development, lactate release
would be an indicator of glycolytic activity in cells [30].
GSH concentration was changed during the cell cycle [31].
Therefore, GSH-dependent enzymes were also subject to such
regulation, particularly as they could contribute to the differences
between the cell lines and also be a factor in their sensitivity to
cytotoxic drugs. High intracellular GSH levels were associated with
apoptotic resistance, and GSH depletion itself was found to trigger
cell death cascades [32]. The study showed that treatment with
kosinostatin involved in the progression of cell death. It is likely
that generation of intracellular reactive oxygen species (ROS) and
depletion of GSH are related to the induction of mitochondria-
dependent cell death in breast cancer cells. Thus, these ﬁndings
supported the hypothesis that oxidative stress plays a role as a
common mediator of cell death by treatment with Streptomyces
secondary metabolite kosinostatin.
Even though p53 is expendable for customary growth, it plays
an essential role in the cellular response to DNA damage from both
endogenous and exogenous sources providing a defensive effect
against tumorigenesis [33]. p53 is activated in response to DNA
damage and many factors interact to signal and modulate this
response [34], and p53 serves as a key relay for signals elicited by
cellular stresses arising from diverse environmental or therapeutic
insults. This relay then activates a cell cycle arrest or cell death
program, depending on the stimulus and cell type. The absence of
p53 function disables the cell death or arrest programmes, thereby
allowing the emergence of variants with various types of genomic
alterations [35]. In human, the p53 tumor suppressor gene is lo-
cated on the short arm of chromosome 17 and its protein product
is a negative regulator of the cell cycle in the G1 phase. Mutations
in the p53 gene are the most frequent alteration in many types of
human malignancy, including lung, colon and breast cancers [36].
Apoptosis is a highly regulated process of programmed cell death,
and disruption of this process reveals a major contributing factor in
the pathology of cancer [37]. Apoptosis is mediated by the action of
caspases, a group of cysteine proteases which can be activated
through two pathways, extrinsic and intrinsic pathways [38]. An-
other major player in apoptosis process is p53, which is activated
when mammalian cells are subjected to stress conditions such as
hypoxia, radiation, DNA damage or chemotherapeutic drugs [39]. It
was reported that the expression of mutant p53 protein in breast
cancer seems to be related to poor prognosis associated with a high
histological grade, epidermal growth factor receptor (EGFR) positiv-
ity, and Bcl-2 and estrogen receptor (ER) negativity [40]. In this study,
the p53 expression in MCF-7 cells treated with kosinostatin was
investigated. Kosinostatin administration on mammary cancer cell
line illustrates increased band intensity of 53 kDa protein. The ac-
cretion of p53 protein indicates the expression of tumor suppressor
protein induced apoptosis by kosinostatin on MCF-7 cells, which
displays that kosinostatin management stimulates the apoptosis.
5. Conclusion
In conclusion, outcome of the present investigation suggests
that the bioactive secondary metabolite from Streptomyces sp.,
V. Rambabu et al. / Journal of Pharmaceutical Analysis 5 (2015) 378–382382kosinostatin, probably gives a stop to proliferation of MCF-7 cells
by induction of apoptosis. It also holds an excellent antimicrobial
activity against various microbial populations. It is concluded that
kosinostatin has antimicrobial property and antiproliferative pro-
spective against MCF-7 cells as a novel source for new anticancer
drugs.Acknowledgments
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